Drugs that contain Givosiran Sodium
1. Drug name - GIVLAARI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8546143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of a target gene |
Jan, 2022
(8 months ago) | |
| US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(1 year, 2 months from now) | |
| US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(1 year, 5 months from now) | |
| US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(1 year, 5 months from now) | |
| US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(2 years from now) | |
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(6 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(7 years from now) | |
| US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(10 years from now) | |
| US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
May, 2033
(10 years from now) | |
| US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(12 years from now) | |
| US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(12 years from now) | |
| CN1630724A | ALNYLAM PHARMS INC | Method For Inhibiting Expression Of Target Gene |
Jan, 2007
(15 years ago) | |
| CN1608131A | ALNYLAM PHARMS INC | Medicine For Treating Pancreatic Cancer |
Jan, 2009
(13 years ago) | |
| CN1608133A | ALNYLAM PHARMS INC | Double-Stranded Ribonucleic Acid For Treating Positive (+) Chain Rna Virus Infection Of Suffers |
Sep, 2009
(13 years ago) | |
| CN1604783A | ALNYLAM PHARMS INC | The Medicine For Treating Fibrosis Disease By Rna Interference |
Dec, 2009
(12 years ago) | |
| CN1650010A | ALNYLAM PHARMS INC | Method For Inhibiting Expression Of Target Gene And Medicine For Treating Tumour Disease |
Jan, 2010
(12 years ago) | |
| CN102006890A | ALNYLAM PHARMS INC | Targeting Lipid |
Oct, 2015
(6 years ago) | |
| CN1835897A | ALNYLAM PHARMS INC | Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank |
Aug, 2024
(1 year, 10 months from now) | |
| CN1835897B | ALNYLAM PHARMS INC | Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank |
Aug, 2024
(1 year, 10 months from now) | |
| CN104540948A | ALNYLAM PHARMS INC | Composition And Method For Inhibiting The Expression Of The Alas1 |
Apr, 2033
(10 years from now) | |
| CN109112131B | ALNYLAM PHARMS INC | Composition And Method For Inhibiting Alas1 Gene Expression |
Apr, 2033
(10 years from now) | |
| CN109112131A | ALNYLAM PHARMS INC | Composition And Method For Inhibiting The Expression Of The Alas1 |
Apr, 2033
(10 years from now) | |
| CN104540948B | ALNYLAM PHARMS INC | Composition And Method For Inhibiting The Expression Of The Alas1 |
Apr, 2033
(10 years from now) | |
| CN105980559B | ALNYLAM PHARMS INC | Composition And Method For Inhibiting Alas1 Gene Expression |
Oct, 2034
(12 years from now) | |
| CN105980559A | ALNYLAM PHARMS INC | Composition And Method For Inhibition Of Alas1 Gene Expression |
Oct, 2034
(12 years from now) | |
| IN200300537P3 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| IN213846B | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| IN200300572P3 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| IN203882B | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Targe Gene |
Jan, 2022
(8 months ago) | |
| IN371332B | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of The Alas1 Gene |
Apr, 2033
(10 years from now) | |
| IN201407093P4 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of The Alas1 Gene |
Apr, 2033
(10 years from now) | |
| IN201647014609A | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of The Alas1 Gene |
Oct, 2034
(12 years from now) | |
| IN392668B | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of The Alas1 Gene |
Oct, 2034
(12 years from now) | |
| EP928290A4 | ALNYLAM PHARMS INC | Oligoribonucleotides And Ribonucleases For Cleaving Rna |
Jun, 2017
(5 years ago) | |
| EP928290B1 | ALNYLAM PHARMS INC | Oligoribonucleotides And Ribonucleases For Cleaving Rna |
Jun, 2017
(5 years ago) | |
| EP928290A1 | ALNYLAM PHARMS INC | Oligoribonucleotides And Ribonucleases For Cleaving Rna |
Jun, 2017
(5 years ago) | |
| EP928290B9 | ALNYLAM PHARMS INC | Oligoribonucleotides And Ribonucleases For Cleaving Rna |
Jun, 2017
(5 years ago) | |
| EP2363479A1 | ALNYLAM PHARMS INC | Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene |
Jan, 2020
(2 years ago) | |
| EP2363479B1 | ALNYLAM PHARMS INC | Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene |
Jan, 2020
(2 years ago) | |
| EP1214945A2 | ALNYLAM PHARMS INC | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1214945A3 | ALNYLAM PHARMS INC | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1214945B2 | ALNYLAM PHARMS INC | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1550719B1 | ALNYLAM PHARMS INC | Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1214945B1 | ALNYLAM PHARMS INC | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1550719A1 | ALNYLAM PHARMS INC | Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1144623A1 | ALNYLAM PHARMS INC | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1144623B1 | ALNYLAM PHARMS INC | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1798285B1 | ALNYLAM PHARMS INC | Methods And Medicament For Inhibition The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1144623B9 | ALNYLAM PHARMS INC | Method And Medicament For Inhibiting The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1798285A1 | ALNYLAM PHARMS INC | Methods And Medicament For Inhibition The Expression Of A Defined Gene |
Jan, 2020
(2 years ago) | |
| EP1349927B1 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease |
May, 2021
(1 year, 4 months ago) | |
| EP1349927A2 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease |
May, 2021
(1 year, 4 months ago) | |
| EP1352061B9 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| EP1352061B1 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| EP1352061A2 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene |
Jan, 2022
(8 months ago) | |
| EP2213736A3 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness |
Jan, 2022
(8 months ago) | |
| EP2213736B1 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness |
Jan, 2022
(8 months ago) | |
| EP2213736A2 | ALNYLAM PHARMS INC | Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness |
Jan, 2022
(8 months ago) | |
| EP1560840A2 | ALNYLAM PHARMS INC | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 29 days from now) | |
| EP1562971A2 | ALNYLAM PHARMS INC | Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation |
Nov, 2023
(1 year, 29 days from now) | |
| EP1560840A4 | ALNYLAM PHARMS INC | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 29 days from now) | |
| EP2957568B1 | ALNYLAM PHARMS INC | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 29 days from now) | |
| EP1560840B1 | ALNYLAM PHARMS INC | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 29 days from now) | |
| EP2957568A1 | ALNYLAM PHARMS INC | Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation |
Nov, 2023
(1 year, 29 days from now) | |
| EP1562971A4 | ALNYLAM PHARMS INC | Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation |
Nov, 2023
(1 year, 29 days from now) | |
| EP1562971B1 | ALNYLAM PHARMS INC | Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation |
Nov, 2023
(1 year, 29 days from now) | |
| EP2216407B1 | ALNYLAM PHARMS INC | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP1605978A2 | ALNYLAM PHARMS INC | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP1605978B1 | ALNYLAM PHARMS INC | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP1605978A4 | ALNYLAM PHARMS INC | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP2216407A3 | ALNYLAM PHARMS INC | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP2216407A2 | ALNYLAM PHARMS INC | Therapeutic Compositions |
Mar, 2024
(1 year, 5 months from now) | |
| EP1615611A4 | ALNYLAM PHARMS INC | Irna Conjugates |
Apr, 2024
(1 year, 6 months from now) | |
| EP1615611B1 | ALNYLAM PHARMS INC | Irna Conjugates |
Apr, 2024
(1 year, 6 months from now) | |
| EP1615611A2 | ALNYLAM PHARMS INC | Irna Conjugates |
Apr, 2024
(1 year, 6 months from now) | |
| EP1620544A4 | ALNYLAM PHARMS INC | Modified Irna Agents |
Apr, 2024
(1 year, 6 months from now) | |
| EP1620544A2 | ALNYLAM PHARMS INC | Modified Irna Agents |
Apr, 2024
(1 year, 6 months from now) | |
| EP1620544B1 | ALNYLAM PHARMS INC | Modified Irna Agents |
Apr, 2024
(1 year, 6 months from now) | |
| EP1765074A2 | ALNYLAM PHARMS INC | Positionally Modified Sirna Constructs |
Jun, 2024
(1 year, 7 months from now) | |
| EP1765074B1 | ALNYLAM PHARMS INC | Positionally Modified Sirna Constructs |
Jun, 2024
(1 year, 7 months from now) | |
| EP1765074A4 | ALNYLAM PHARMS INC | Positionally Modified Sirna Constructs |
Jun, 2024
(1 year, 7 months from now) | |
| EP1667944B1 | ALNYLAM PHARMS INC | Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour |
Aug, 2024
(1 year, 10 months from now) | |
| EP1667944A1 | ALNYLAM PHARMS INC | Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour |
Aug, 2024
(1 year, 10 months from now) | |
| EP1677822A2 | ALNYLAM PHARMS INC | 4'-Thionucleosides And Oligomeric Compounds |
Sep, 2024
(1 year, 11 months from now) | |
| EP1677822A4 | ALNYLAM PHARMS INC | 4'-Thionucleosides And Oligomeric Compounds |
Sep, 2024
(1 year, 11 months from now) | |
| EP1677822B1 | ALNYLAM PHARMS INC | 4'-Thionucleosides And Oligomeric Compounds |
Sep, 2024
(1 year, 11 months from now) | |
| EP1799270A2 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes |
Sep, 2025
(2 years from now) | |
| EP1799270B1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes |
Sep, 2025
(2 years from now) | |
| EP1799270A4 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes |
Sep, 2025
(2 years from now) | |
| EP2231195B1 | ALNYLAM PHARMS INC | Targeting Lipids |
Dec, 2028
(6 years from now) | |
| EP2231194A2 | ALNYLAM PHARMS INC | Folate-Irna Conjugates |
Dec, 2028
(6 years from now) | |
| EP2231194B1 | ALNYLAM PHARMS INC | Folate-Irna Conjugates |
Dec, 2028
(6 years from now) | |
| EP3156077A1 | ALNYLAM PHARMS INC | Targeting Lipids |
Dec, 2028
(6 years from now) | |
| EP3156077B1 | ALNYLAM PHARMS INC | Targeting Lipids |
Dec, 2028
(6 years from now) | |
| EP2231195A2 | ALNYLAM PHARMS INC | Targeting Lipids |
Dec, 2028
(6 years from now) | |
| EP2836595A2 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of The Alas1 Gene |
Apr, 2033
(10 years from now) | |
| EP2836595B1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of The Alas1 Gene |
Apr, 2033
(10 years from now) | |
| EP3052628B1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of The Alas1 Gene |
Oct, 2034
(12 years from now) | |
| EP3052628A1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of The Alas1 Gene |
Oct, 2034
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(10 years from now) | |
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 189MG BASE/ML (EQ 189MG BASE/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.